Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Accelrys Integrate Cell Imaging Software

NEW YORK (GenomeWeb News) – PerkinElmer has integrated its image data management system for high content screening with Accelrys' data analysis and reporting platform, PerkinElmer.

PerkinElmer's Columbus software will provide detailed images containing single cells and "large amounts of cell data," and Accelrys' Pipeline Platform will deliver "intelligent algorithms and image analysis data transfer capability," PerkinElmer said.

"The outcome of this integration will enable scientists to apply all the data and statistical analysis they are used to seeing from a well based level to a single cell level, allowing deeper understanding of cellular processes," Accelrys VP and Chief Scientific Officer Frank Brown said in a statement. "The use of machine learning and computer automation on the large amounts of data generated brings the early promise of high content screening to fruition."

The collaboration will give researchers "access to multiplexed cellular information including morphology, intensity, complexity, and intensity of specific compartments, as well as fluorescence, translocation, morphology changes, and texture analysis, among other read outs," said Richard Eglen, PerkinElmer's president of Bio-discovery.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.